Amit Shah’s son’s company grew by 16,000 times in one year

News Network
October 8, 2017

New Delhi, Oct 8: The Congress and the Aam Aadmi Party on Sunday took a dig at the NDA government over a report that the company owned by Amit Shah’s son recorded a massive 16,000-times increase in turnover over in the year following the election of Narendra Modi as prime minister and the elevation of Shah to the post of party president.

The Opposition parties have sought answers from Prime Minister and the BJP president, and demanded a probe by the ED and the CBI.

Addressing a press conference at the AICC headquarters, senior Congress leader Kapil Sibal said it seems the fortunes of some people have changed after the change of power. He said filings with the Registrar of Companies (RoC) have revealed that the company owned by Shah’s son Jay started making profits after 2014. The story was reported by The Wire today.

He said in March 2013 and in March 2014, Shah’s Temple Enterprise Private Ltd recorded losses of Rs 6,230 and Rs 1,724 respectively. “In 2014-15 it started making profits…that means there was some change in May and profit ka karvah shuru ho gaya….”

“In 2014-15, the company made a profit of Rs 18,728. The real change happened in 2015-16 and it is shocking…..The company made a turnover of Rs 80 crore in 2015-16. The company started getting loans. One Rajesh Khandwala, who owns KIFS Financial Services, gave a loan of Rs 15.78 crore. And the company stopped business activities in October 2016. And the reason stated was that the company was incurring losses.”

“Today, we want to ask our Prime Minister what you now think about crony capitalism. Will you direct the CBI to probe? Will you direct the ED to probe? Will you ask them to arrest them? Because in the case of opposition, the ED immediately sends notice and shows speed in arresting them…If somebody’s name is Jai, Amit and Shah who can arrest them. I can confidently tell you that the Prime Minister will remain silent,” Sibal said.

He alleged he has learnt that the electronic media has been asked not to show his press conference.

“Our pradhan sevak always used to talk about crony capitalism. Even if there is an allegation of Rs 10 lakh against anyone, they set the CBI after them. They set the ED after him. If they want to level any allegation against a Congress leader….there was an allegation of Rs 10 crore against Virbhadra Singh….how many cases did they launch…So we want to ask where is the CBI, ED and where is the prime minister.”

“The Prime Minister will not speak. Because it is about the son of his party’s president. Unhi ki ho jai wo hain? So how suddenly there was a turnover of Rs 80 crore..this company was dealing in agri products….” he said.

Asked where is the criminality, he said “we are talking about crony capitalism. Criminality will only (be established) if there is an investigation. That will only be determined by an investigation. Why where these loans given through ooperative banks without a mortgage, without proper security. Seven crore was the turnover of the cooperative bank and loan of Rs 25 crore was given…why,” he asked.

He spoke about Kusum Finserve, a limited liability partnership incorporated in July 2015 with Jay Shah owning a 60 per cent stake in it. He said the got company got Rs 25 crore loan from the Kalupur Commercial Cooperative Bank. The board of directors of the bank, he said, include individuals from the Nirma group and Nirma university.

Asked whether the Congress will seek an investigation, he said “investigation is to be done by agencies under their control. Who will listen to the Congress. We just want you to tell the people of India that this is happening in our country. We know who CBI, ED will investigate and who ED and CBI will not investigate. Is the Prime Minister open and honest enough to say investigate the son of Amit Shah. That is the issue.”

“Our appeal to the Prime Minister is that you are the pradhan sevak ….you always say na khaunga, na khane dunga….tho nahin khane dijiye.” “This is the Shah model of business…,” he said.

Defending Jay Shah, BJP’s national IT cell chief Amit Malviya, in a series of tweets, said: “Every new business starts with nil turnover on day one, expands later. What is wrong with legitimate expansion of business?  This was a legitimate commodity export import business, where volumes are high and margins are low so 16,000x misleading. Is Jay Shah not allowed to take loan on market rates of interest from a registered NBFC? Where is the favour / impropriety? Since when has taking a loan by cheque become illegal? Jay Shah company took a loan from NBFC, disclosed it in income tax.”

Meanwhile, Congress vice president Rahul Gandhi tweeted: “We finally found the only beneficiary of Demonetisation. It’s not the RBI, the poor or the farmers. It’s the Shah-in-Shah of Demo. Jai Amit,”

The AAP also held a press conference. Senior leader Ashuthosh said a FIR should be registered against Jay Shah and a probe should be ordered into his company’s activities.

Comments

ahmed
 - 
Monday, 9 Oct 2017

ha haa ACCHA DIN AAYA HEY SIRF MODI PARIVIAR Ko...

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 1,2020

Mangaluru, Jul 1: The Bajpe police station under the limits of Mangaluru City Police Commissionerate has been sealed down after an arrested accused was tested positive for the Coronavirus.

Police said on Wednesday that the Bajpe police arrested two persons in connection with plotting dacoity in Oddidakala in Bajpe. After the arrest, their throat swab was sent for a test. On Wednesday, one of the accused tested positive for the Coronavirus.

In this connection, the Bajpe police station has been sealed down and the police personnel who were present during the arrest are placed under home quarantine.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 26,2020

Bengaluru, Mar 26: The number of COVI D-19 cases in Karnataka spiked to 55 on Thursday after four new cases were reported. 

According to official sources, a 35-year-old man, who was a resident of Nanjanagud town in Mysuru taluk and worked in a pharma unit, tested positive for coronavirus. 

He had been quarantined in his home and efforts are being made to track down as many as seven persons, who had primary contact with 
him.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.